September 1994
Volume 35, Issue 10
Free
Articles  |   September 1994
Promotion of corneal allograft survival with leflunomide.
Author Affiliations
  • J Y Niederkorn
    Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas 75235.
  • L S Lang
    Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas 75235.
  • J Ross
    Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas 75235.
  • J Mellon
    Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas 75235.
  • S M Robertson
    Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas 75235.
Investigative Ophthalmology & Visual Science September 1994, Vol.35, 3783-3785. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J Y Niederkorn, L S Lang, J Ross, J Mellon, S M Robertson; Promotion of corneal allograft survival with leflunomide.. Invest. Ophthalmol. Vis. Sci. 1994;35(10):3783-3785.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

PURPOSE: The efficacy of the antirejection drug leflunomide was evaluated in a rat model of penetrating keratoplasty. METHODS: Corneal grafts from inbred Lewis rats were transplanted orthotopically to inbred Wistar-Furth (WF) recipients. WF rats received either Leflunomide (HWA 486), the active metabolite of leflunomide (A77-1726A), or cyclosporin A, administered orally beginning 2 days before transplantation and continuing for 30 days thereafter. Graft survival was assessed clinically three times per week, and mean survival times were determined. RESULTS: Oral administration of either leflunomide or the salt of its active metabolite resulted in a significant prolongation of graft survival time. Moreover, almost one third of the grafts survived for an additional 3 weeks, even after drug treatment was discontinued. CONCLUSION: The results indicate that leflunomide holds considerable promise as an antirejection drug for use in recipients of corneal transplants in whom cyclosporin A and steroids are contraindicated.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×